Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,717 | -6,635 | -4,022 | -27,424 | -14,412 |
| Depreciation Amortization | 0 | N/A | N/A | 904 | 591 |
| Accounts payable and accrued liabilities | 19 | -89 | -11 | 109 | 92 |
| Other Working Capital | 602 | 445 | 236 | 544 | 328 |
| Other Operating Activity | 2,156 | 2,100 | 1,683 | 16,263 | 6,293 |
| Operating Cash Flow | $-5,940 | $-4,179 | $-2,114 | $-9,605 | $-7,108 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-3 | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,352 | 6,352 | 6,352 | N/A | -35 |
| Common Stock Repurchased | N/A | N/A | N/A | -300 | -300 |
| Other Financing Activity | -53 | 0 | 0 | -89 | 0 |
| Financing Cash Flow | $6,299 | $6,352 | $6,352 | $-389 | $-335 |
| Beginning Cash Position | 6,504 | 6,504 | 6,504 | 16,498 | 16,498 |
| End Cash Position | 6,861 | 8,677 | 10,742 | 6,504 | 9,055 |
| Net Cash Flow | $357 | $2,174 | $4,238 | $-9,994 | $-7,443 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,940 | -4,179 | -2,114 | -9,605 | -7,108 |
| Capital Expenditure | -3 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -5,942 | -4,179 | -2,114 | -9,605 | -7,108 |